CISBIO Announces FDA Approval of MESOMARK® Assay Now Available to Physicians in the U.S. for Monitoring Patients with Mesothelioma
European developer and marketer CISBIO has announced that the U.S. Food and Drug Administration (FDA) has approved MESOMARK® Assay, the first in-vitro test for managing patients with mesothelioma, for use. The test is now available for monitoring patients who suffer from epithelioid or biphasic mesothelioma. The introduction of a minimally invasive monitoring agent with a greater diagnostic capacity is a key element in the ongoing treatment of mesothelioma, as treatment monitoring has traditionally been costly and quite invasive.
The test has been developed and manufactured by Fujirebio Diagnostics, Inc. and is being marketed by CISBIO.